Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07103135 · ClinicalTrials.gov registry record · Phase 1

Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling

A Phase 1 study of Chronic Pain, sponsored by University of Minnesota.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT07103135: Recruiting Phase 1 study of Chronic Pain, sponsored by University of Minnesota.

NCT07103135 is a Phase 1 study of Chronic Pain that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 30 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07103135, a Phase 1 study of Chronic Pain, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and efficacy of accelerated intermittent theta burst stimulation (aiTBS) targeting personalized nodes within the somato-cognitive action network (SCAN) and action motor network (AMN) for the treatment of chronic pain. The study will employ Thompson Sampling, a Bayesian reinforcement learning algorithm, to optimize stimulation site selection based on individual response patterns. This approach has the potential to revolutionize pain management by improving treatment accessibility through shortened timelines, addressing individual variations in pain networks through precision targeting, and potentially achieving more robust pain relief through accelerated neuroplasticity. The specific aims of the study are: 1. To establish the relationship between SCAN and AMN connectivity and cognitive- affective pain symptoms. 2. To evaluate the efficacy of Thompson Sampling-optimized aiTBS across SCAN and AMN on affective and sensorimotor pain dimensions. 3. To identify fMRI connectivity biomarkers predictive of treatment response and remission.

Primary Outcome

measured by the Numerical Rating Scale (NRS) from baseline to after completion of the trial (approximately 3 months). For the NRS, the scores range from 0 to 10, where 0 indicates no pain (better outcome) and 10 is the worst pain that the participant can imagine (worse outcome)

Conditions Studied

Interventions

  • DEVICE MagVenture X100 Pro transcranial magnetic stimulation system

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-03-01
Est. Completion 2030-08-31
Phase Phase 1
University of Minnesota

966 total trials

What NCT07103135 shows while recruiting

NCT07103135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which MagVenture X100 Pro transcranial magnetic stimulation system is the first listed.

NCT07103135 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT07103135 about?

NCT07103135 is a clinical study titled "Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling". The purpose of this study is to evaluate the safety and efficacy of accelerated intermittent theta burst stimulation (aiTBS) targeting personalized nodes within the somato-cognitive action network (SCAN) and action motor network (AMN) for the treatment of chronic pain. The study will employ Thompson...

What is the current status of trial NCT07103135?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-01. Estimated completion is 2030-08-31.

What conditions does trial NCT07103135 study?

This clinical trial studies the following conditions: Chronic Pain.

What interventions are being tested in trial NCT07103135?

The interventions under investigation include: MagVenture X100 Pro transcranial magnetic stimulation system (DEVICE).

Who is sponsoring clinical trial NCT07103135?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07103135 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07103135's enrollment target sits among peer trials

30 244th of 301 higher than 48 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07103135, the US trial registry maintained by the National Library of Medicine. NCT07103135 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.